SG10201500416RA - Methods of Treating Autoimmune Diseases with DLL4 Antagonists - Google Patents
Methods of Treating Autoimmune Diseases with DLL4 AntagonistsInfo
- Publication number
- SG10201500416RA SG10201500416RA SG10201500416RA SG10201500416RA SG10201500416RA SG 10201500416R A SG10201500416R A SG 10201500416RA SG 10201500416R A SG10201500416R A SG 10201500416RA SG 10201500416R A SG10201500416R A SG 10201500416RA SG 10201500416R A SG10201500416R A SG 10201500416RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- autoimmune diseases
- treating autoimmune
- dll4 antagonists
- dll4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29980110P | 2010-01-29 | 2010-01-29 | |
| US36168710P | 2010-07-06 | 2010-07-06 | |
| US38869710P | 2010-10-01 | 2010-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500416RA true SG10201500416RA (en) | 2015-04-29 |
Family
ID=43925413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201500416RA SG10201500416RA (en) | 2010-01-29 | 2011-01-28 | Methods of Treating Autoimmune Diseases with DLL4 Antagonists |
| SG2012052056A SG182528A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating autoimmune diseases with dll4 antagonists |
| SG2012052049A SG182527A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating diabetes with dll4 antagonists |
| SG10201500404QA SG10201500404QA (en) | 2010-01-29 | 2011-01-28 | Methods of Treating Diabetes with DLL4 Antagonists |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012052056A SG182528A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating autoimmune diseases with dll4 antagonists |
| SG2012052049A SG182527A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating diabetes with dll4 antagonists |
| SG10201500404QA SG10201500404QA (en) | 2010-01-29 | 2011-01-28 | Methods of Treating Diabetes with DLL4 Antagonists |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8889133B2 (fr) |
| EP (2) | EP2528945B1 (fr) |
| JP (2) | JP5997613B2 (fr) |
| KR (2) | KR101832118B1 (fr) |
| CN (2) | CN102947336B (fr) |
| AR (1) | AR080026A1 (fr) |
| AU (2) | AU2011210773B2 (fr) |
| BR (2) | BR112012018766A2 (fr) |
| CA (2) | CA2787394C (fr) |
| CY (2) | CY1118223T1 (fr) |
| DK (2) | DK2528945T3 (fr) |
| ES (2) | ES2605430T3 (fr) |
| HR (2) | HRP20170130T1 (fr) |
| HU (2) | HUE031432T2 (fr) |
| IL (2) | IL220887A (fr) |
| JO (2) | JO3183B1 (fr) |
| LT (2) | LT2528946T (fr) |
| MX (2) | MX343553B (fr) |
| MY (2) | MY156538A (fr) |
| PL (2) | PL2528946T3 (fr) |
| PT (2) | PT2528946T (fr) |
| RS (2) | RS55715B1 (fr) |
| RU (2) | RU2587620C2 (fr) |
| SG (4) | SG10201500416RA (fr) |
| SI (2) | SI2528946T1 (fr) |
| SM (2) | SMT201600412B (fr) |
| TW (2) | TWI600433B (fr) |
| UY (1) | UY33206A (fr) |
| WO (2) | WO2011094467A2 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| NZ598524A (en) | 2009-08-29 | 2014-06-27 | Abbvie Inc | Therapeutic dll4 binding proteins |
| ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| CN105037543B (zh) | 2010-03-02 | 2020-11-03 | Abbvie 公司 | 治疗性dll4结合蛋白 |
| PL3485903T3 (pl) | 2011-09-23 | 2023-06-12 | Mereo Biopharma 5, Inc. | Środki wiążące VEGF/DLL4 i ich zastosowania |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| TW201438736A (zh) * | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| CA2917402C (fr) | 2013-07-09 | 2019-10-22 | Hanwha Chemical Corporation | Nouvelles proteines a double cible se liant specifiquement a dll4 et vegf et son utilisation |
| CN111239415B (zh) * | 2013-10-17 | 2024-03-26 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| KR102459720B1 (ko) * | 2014-04-08 | 2022-10-26 | 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. | 자가면역 질환의 치료를 위한 조합 요법 |
| CN107530419B (zh) | 2014-10-31 | 2021-05-18 | 昂考梅德药品有限公司 | 治疗疾病的组合疗法 |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| US11446262B2 (en) | 2018-11-29 | 2022-09-20 | Debora Zucco Sassi Yonezawa Siviglia | Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination |
| EP3886856A4 (fr) | 2018-11-29 | 2022-01-19 | Zucco Sassi Yonezawa Siviglia, Debora | Procédé de traitement ou de prévention de crises associées à un trouble épileptique |
| WO2022210802A1 (fr) * | 2021-03-30 | 2022-10-06 | 国立大学法人熊本大学 | Agent thérapeutique pour l'atrophie musculaire |
| WO2023159166A1 (fr) * | 2022-02-18 | 2023-08-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anticorps à domaine unique (nanocorps) ciblant le ligand notch dll4 et leurs méthodes d'utilisation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| CA2486712C (fr) * | 2002-05-21 | 2012-01-03 | Cv Therapeutics, Inc. | Methode permettant de traiter le diabete |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| CA2630839C (fr) * | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4 |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| WO2008060705A2 (fr) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anticorps anti-dll4 et leurs procédés d'utilisation |
| MY150092A (en) | 2006-08-07 | 2013-11-29 | Regeneron Pharma | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| BRPI0717431A2 (pt) | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| NZ598524A (en) | 2009-08-29 | 2014-06-27 | Abbvie Inc | Therapeutic dll4 binding proteins |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
-
2011
- 2011-01-23 JO JOP/2011/0021A patent/JO3183B1/ar active
- 2011-01-26 AR ARP110100250A patent/AR080026A1/es unknown
- 2011-01-28 EP EP11701735.0A patent/EP2528945B1/fr active Active
- 2011-01-28 PT PT117019331T patent/PT2528946T/pt unknown
- 2011-01-28 SG SG10201500416RA patent/SG10201500416RA/en unknown
- 2011-01-28 TW TW105101963A patent/TWI600433B/zh not_active IP Right Cessation
- 2011-01-28 MX MX2012008740A patent/MX343553B/es active IP Right Grant
- 2011-01-28 HU HUE11701933A patent/HUE031432T2/en unknown
- 2011-01-28 UY UY0001033206A patent/UY33206A/es not_active Application Discontinuation
- 2011-01-28 ES ES11701735.0T patent/ES2605430T3/es active Active
- 2011-01-28 PL PL11701933T patent/PL2528946T3/pl unknown
- 2011-01-28 DK DK11701735.0T patent/DK2528945T3/en active
- 2011-01-28 WO PCT/US2011/022817 patent/WO2011094467A2/fr active Application Filing
- 2011-01-28 RS RS20170142A patent/RS55715B1/sr unknown
- 2011-01-28 BR BR112012018766A patent/BR112012018766A2/pt active Search and Examination
- 2011-01-28 TW TW100103219A patent/TWI564019B/zh not_active IP Right Cessation
- 2011-01-28 EP EP11701933.1A patent/EP2528946B1/fr active Active
- 2011-01-28 MY MYPI2012003169A patent/MY156538A/en unknown
- 2011-01-28 KR KR1020127022506A patent/KR101832118B1/ko active IP Right Grant
- 2011-01-28 AU AU2011210773A patent/AU2011210773B2/en active Active
- 2011-01-28 CN CN201180016820.4A patent/CN102947336B/zh not_active Expired - Fee Related
- 2011-01-28 RS RS20170036A patent/RS55595B1/sr unknown
- 2011-01-28 CA CA2787394A patent/CA2787394C/fr active Active
- 2011-01-28 HU HUE11701735A patent/HUE032985T2/en unknown
- 2011-01-28 WO PCT/US2011/022810 patent/WO2011094465A1/fr active Application Filing
- 2011-01-28 JP JP2012551293A patent/JP5997613B2/ja active Active
- 2011-01-28 SM SM201600412T patent/SMT201600412B/it unknown
- 2011-01-28 KR KR1020127022496A patent/KR101797918B1/ko active IP Right Grant
- 2011-01-28 PT PT117017350T patent/PT2528945T/pt unknown
- 2011-01-28 BR BR112012018820A patent/BR112012018820A8/pt not_active Application Discontinuation
- 2011-01-28 MY MYPI2012003168A patent/MY156353A/en unknown
- 2011-01-28 SI SI201131020A patent/SI2528946T1/sl unknown
- 2011-01-28 US US13/015,652 patent/US8889133B2/en active Active
- 2011-01-28 SG SG2012052056A patent/SG182528A1/en unknown
- 2011-01-28 PL PL11701735T patent/PL2528945T3/pl unknown
- 2011-01-28 LT LTEP11701933.1T patent/LT2528946T/lt unknown
- 2011-01-28 SG SG2012052049A patent/SG182527A1/en unknown
- 2011-01-28 JP JP2012551294A patent/JP5883801B2/ja active Active
- 2011-01-28 AU AU2011210771A patent/AU2011210771B2/en active Active
- 2011-01-28 CA CA2787615A patent/CA2787615C/fr active Active
- 2011-01-28 RU RU2012136816/10A patent/RU2587620C2/ru not_active IP Right Cessation
- 2011-01-28 US US13/015,637 patent/US8765125B2/en active Active
- 2011-01-28 SI SI201131011A patent/SI2528945T1/sl unknown
- 2011-01-28 CN CN2011800165511A patent/CN102884081A/zh active Pending
- 2011-01-28 RU RU2012136817/10A patent/RU2587624C2/ru not_active IP Right Cessation
- 2011-01-28 SG SG10201500404QA patent/SG10201500404QA/en unknown
- 2011-01-28 ES ES11701933.1T patent/ES2609663T3/es active Active
- 2011-01-28 LT LTEP11701735.0T patent/LT2528945T/lt unknown
- 2011-01-28 MX MX2012008638A patent/MX343555B/es active IP Right Grant
- 2011-01-28 DK DK11701933.1T patent/DK2528946T3/en active
-
2012
- 2012-07-11 IL IL220887A patent/IL220887A/en not_active IP Right Cessation
- 2012-07-11 IL IL220889A patent/IL220889A/en not_active IP Right Cessation
-
2014
- 2014-05-22 US US14/285,409 patent/US20140255429A1/en not_active Abandoned
-
2016
- 2016-11-14 CY CY20161101167T patent/CY1118223T1/el unknown
-
2017
- 2017-01-04 CY CY20171100010T patent/CY1118551T1/el unknown
- 2017-01-16 SM SM201700021T patent/SMT201700021B/it unknown
- 2017-01-26 HR HRP20170130TT patent/HRP20170130T1/hr unknown
- 2017-02-16 HR HRP20170249TT patent/HRP20170249T1/hr unknown
- 2017-03-19 JO JOP/2017/0065A patent/JO3242B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170249T1 (hr) | Načini liječenja autoimunih bolesti antagonistima gena dll4 | |
| HRP20171352T1 (hr) | Wnt-antagonisti i postupci liječenja | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| ZA201301601B (en) | Treatment of diseases | |
| EP2717855A4 (fr) | Procédés de traitement | |
| HK1197072A1 (en) | Mcam antagonists and methods of treatment mcam | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| EP2613786A4 (fr) | Traitement de maladies | |
| EP2709991A4 (fr) | Utilisation d'antagonistes de cxcr4 | |
| EP2731429A4 (fr) | Composés, procédés de préparation et procédés d'utilisation | |
| IL256026A (en) | Treatment methods | |
| ZA201208389B (en) | Treatment of proliferative diseases | |
| EP2709999A4 (fr) | Composés de quinazoline-7-éther et méthodes d'utilisation | |
| EP2608804A4 (fr) | Traitement de maladies rénales | |
| EP2616812A4 (fr) | Procédés de traitement de maladies auto-immunes avec des anticorps anti-fceri | |
| EP2556161A4 (fr) | Procédés de traitement de maladies auto-immunes | |
| IL222690A0 (en) | Treatment of autoimmune diseases | |
| PT2709991T (pt) | Uso de antagonistas de cxcr4 para tratar síndrome de whim, mielocatexia, neutropenia e linfocitopenia | |
| GB201019938D0 (en) | Determination of therapeutic agents | |
| GB201110602D0 (en) | Methods of treatment | |
| GB201109737D0 (en) | Methods of treatment |